- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07357285
A biztonságosság és hatékonyság értékelése az iNstroke 4F tromboaszpirációs katéterrel kapcsolatban akut ischaemiás stroke-ban szenvedő betegeknél, akiknél a stroke oka primer distalis közepes méretű ér elzáródás (DMVO) (4-NiVO)
Prospektív, egykarú, multicentrikus vizsgálat a iNstroke 4F trombóaszpirációs katéter hatékonyságának és biztonságosságának értékelésére akut ischaemiás stroke-ban szenvedő betegekben, amelyet primer distális közepes ér elzáródások (DMVO) okoznak.
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.
In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Budapest, Magyarország
- Semmelweis University Center
-
-
-
-
-
Bonn, Németország
- Universitätsklinikum Bonn
-
Kiel, Németország
- Universitätsklinikum Schleswig-Holstein
-
Marburg, Németország
- Klinikum Marburg
-
Nuremberg, Németország
- Klinikum Nürnberg
-
Recklinghausen, Németország
- Knappschaftskrankenhaus Recklinghausen
-
-
-
-
-
Barcelona, Spanyolország
- Hospital Universitario Vall d'Hebron
-
Madrid, Spanyolország
- Hospital Universitario 12 de Octubre
-
Madrid, Spanyolország
- Hospital Universitario La Paz
-
Madrid, Spanyolország
- Hospital Universitario de Getafe
-
Murcia, Spanyolország
- Hospital Clínico Universitario Virgen de Arrixaca
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects with symptom onset up to 24 hours.
- Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥5 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
Exclusion Criteria:
- Subjects aged < 18.
- Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
- Baseline NIHSS score <5 assessed before the procedure.
- Pre-stroke mRS score >2.
- Subjects with an ASPECTS score <6.
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
- Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
- Subjects participating in a clinical trial at the moment of the inclusion.
- Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Egyéb: Thromboaspiration using iNstroke 4F aspiration catheter
No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose. |
Patients to undergo thromboaspiration with iNstroke 4F |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR. |
Intra-procedure
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy |
Intra-procedure
|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR. |
Intra-procedure
|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter. |
Intra-procedure
|
|
Clinical Endpoint
Időkeret: 90 day
|
Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit. |
90 day
|
|
Safety Endpoint
Időkeret: 24 (-8/+12) hours
|
Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT). Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration. |
24 (-8/+12) hours
|
|
Safety Endpoint
Időkeret: Intra-procedure
|
Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
Időkeret: Intra-procedure
|
Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
Időkeret: During hospital admission
|
Inhospital mortality rate related to the procedure during hospital admission. |
During hospital admission
|
|
Safety Endpoint
Időkeret: 90 days (±14 days) after the procedure.
|
Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure. |
90 days (±14 days) after the procedure.
|
|
Safety Endpoint
Időkeret: Intra-procedure
|
Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel. |
Intra-procedure
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Exploratory Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Időkeret: Intra-procedure
|
Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Időkeret: Intra-procedure
|
Number of passes with iNstroke 4F aspiration catheter until recanalization. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Időkeret: Intra-procedure
|
Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score). |
Intra-procedure
|
|
Exploratory Clinical Endpoint
Időkeret: 24 (-8/+12) hours post-procedure.
|
Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure. |
24 (-8/+12) hours post-procedure.
|
|
Exploratory Clinical Endpoint
Időkeret: First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first. |
First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
|
Exploratory Clinical Endpoint
Időkeret: 24 (-8/+12) hours.
|
Median of NIHSS score at 24 (-8/+12) hours. |
24 (-8/+12) hours.
|
|
Exploratory Clinical Endpoint
Időkeret: 3 days (±24 hours) post procedure
|
Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first. |
3 days (±24 hours) post procedure
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 4-NiVO-01
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .